QR код

Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies

Abstract Chimeric antigen receptor T (CAR-T) cell therapy may achieve long-lasting remission in patients with B-cell malignancies not responding to conventional therapies. However, potentially severe and hard-to-manage side effects, including cytokine release syndrome (CRS), neurotoxicity and macrop...

Повний опис

Збережено в:
Автори: Simona Manni, Francesca Del Bufalo, Pietro Merli, Domenico Alessandro Silvestris, Marika Guercio, Simona Caruso, Sofia Reddel, Laura Iaffaldano, Michele Pezzella, Stefano Di Cecca, Matilde Sinibaldi, Alessio Ottaviani, Maria Cecilia Quadraccia, Mariasole Aurigemma, Andrea Sarcinelli, Roselia Ciccone, Zeinab Abbaszadeh, Manuela Ceccarelli, Rita De Vito, Maria Chiara Lodi, Maria Giuseppina Cefalo, Angela Mastronuzzi, Biagio De Angelis, Franco Locatelli, Concetta Quintarelli
Формат: Artigo
Мова:Inglês
Опубліковано: Nature Portfolio 2023-06-01
Серія:Nature Communications
Онлайн доступ:https://doi.org/10.1038/s41467-023-38723-y
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси